Back to top
more

STEALTH BIOTHER (MITO)

(Delayed Data from NSDQ)

$14.62 USD

14.62
868

-0.26 (-1.75%)

Updated May 3, 2019 11:05 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Stealth (MITO) Files NDA for Ultra-Rare Disease Candidate

Stealth BioTherapeutics (MITO) files a new drug application for elamipretide to the FDA for the treatment of Barth syndrome, an ultra-rare genetic condition.

Stealth BioTherapeutics (MITO) Sees Hammer Chart Pattern: Time to Buy?

Stealth BioTherapeutics (MITO) has been struggling lately, but the selling pressure may be coming to an end soon.

Stealth BioTherapeutics Corp (MITO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

Stealth BioTherapeutics Corp (MITO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020

Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength

Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.

Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance

Alexion (ALXN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

Company News For Oct 11, 2019

Companies in the news are: RARX, BBBY, PCG, MITO

Alexion (ALXN) Collaborates With Stealth BioTherapeutics

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

Stealth BioTherapeutics Enters Oversold Territory

Stealth BioTherapeutics Corp (MITO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Stealth BioTherapeutics Sees Hammer Chart Pattern: Time to Buy?

Stealth BioTherapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Celgene (CELG) Hits 52-Week High, Can the Run Continue?

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.